These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25987043)

  • 1. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
    Raj U; Kumar H; Gupta S; Varadwaj PK
    Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation.
    Luo M; Wang H; Zou Y; Zhang S; Xiao J; Jiang G; Zhang Y; Lai Y
    J Mol Graph Model; 2016 Jul; 68():128-139. PubMed ID: 27434826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
    Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
    Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging roles of DOT1L in leukemia and normal development.
    McLean CM; Karemaker ID; van Leeuwen F
    Leukemia; 2014 Nov; 28(11):2131-8. PubMed ID: 24854991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
    Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
    Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
    Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
    J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The upstreams and downstreams of H3K79 methylation by DOT1L.
    Vlaming H; van Leeuwen F
    Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
    Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
    Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D Structure Generation, Molecular Dynamics and Docking Studies of IRHOM2 Protein Involved in Cancer & Rheumatoid Arthritis.
    Raj U; Kumar H; Varadwaj PK
    Curr Comput Aided Drug Des; 2015; 11(4):325-35. PubMed ID: 26603928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
    Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
    Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness.
    Kari V; Raul SK; Henck JM; Kitz J; Kramer F; Kosinsky RL; Übelmesser N; Mansour WY; Eggert J; Spitzner M; Najafova Z; Bastians H; Grade M; Gaedcke J; Wegwitz F; Johnsen SA
    Clin Epigenetics; 2019 Jan; 11(1):4. PubMed ID: 30616689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer-Aided Discovery of Massonianoside B as a Novel Selective DOT1L Inhibitor.
    Chen J; Park HJ
    ACS Chem Biol; 2019 May; 14(5):873-881. PubMed ID: 30951287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-guided DOT1L probe optimization by label-free ligand displacement.
    Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
    ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
    Anglin JL; Song Y
    J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.